The pediatric clinical trial market is anticipated to expand at a CAGR of 5.9% during the projected period. The market value is projected to increase from US$ 17,918.1 million in 2024 to US$ 31,661.0 million by 2034. The market was valued at US$ 16,831.0 million in 2023 and grew at a CAGR of 6.5% from 2019 to 2023.
| Attributes | Details |
|---|---|
| Pediatric Clinical Trial Market Value (2024) | US$ 17,918.1 million |
| Projected Market Value (2034) | US$ 31,661.0 million |
| CAGR (2024 to 2034) | 5.9% |
Due to the pediatric population's unmet healthcare needs, there is a sizable product pipeline in the clinical development phase. The pediatric clinical trial market is likely to acquire a strong pipeline for developing new medications shortly.
The market is driven by the rising awareness of pediatric medicines, outsourcing internal clinical trials to CROs, and the rising prevalence of pediatric diseases like diabetes. North America is expected to dominate the market during the projection period.
The growing prevalence of illnesses in the pediatric population bolsters clinical trials and research efforts to develop specific drugs. The demand for pediatric clinical trials is driven by various factors in the global market.
| Attributes | Details |
|---|---|
| Market Value for 2019 | US$ 14,118.8 million |
| Market Value for 2023 | US$ 16,831.0 million |
| Market CAGR from 2019 to 2023 | 4.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Principal Consultant
| Leading Area | Oncology |
|---|---|
| Market Share in 2024 | 21.8% |
| Leading Sponsor | Industry |
|---|---|
| Market Share in 2024 | 50.7% |
| Leading Phase | Phase 3 |
|---|---|
| Segment CAGR | 46.9% |
The pediatric clinical trial market can be observed in the subsequent tables, which focus on the leading economies in India, China, France, Germany, and the United States. A comprehensive evaluation demonstrates that India has enormous opportunities due to its resilient pediatric clinical trial manufacturers.
| Countries | CAGR (2024 to 2034) |
|---|---|
| India | 14.1% |
| China | 11.7% |
| France | 7.1% |
| United States | 3% |
| Germany | 2.5% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Leading pediatric clinical trial providers, such as Synteract, ICON Plc., Syneos Health, Medpace, Inc., PPD Inc., Premier Research, LabCorp Drug Development, QPS Holding, Pfizer Inc., and The Emmes Company, LLC, as well as IQVIA Inc., dominate the competitive landscape. These pediatric clinical trial vendors use their resources and experience in pediatric healthcare research to drive innovation and determine the sector's course.
Notable industry leaders in pediatric pharmaceutical trials, Synteract, ICON Plc., and Syneos Health, are renowned for their broad skills and all-inclusive services. With their specialist solutions, Medpace, Inc., PPD Inc., and Premier Research enhance the competitive landscape with substantial knowledge. The market is strengthened and diversified by the acquisition of LabCorp Drug Development, QPS Holding, and Pfizer Inc., which enhances the pediatric clinical trial ecosystem.
The Emmes Company, LLC and IQVIA Inc. contribute breadth and depth, guaranteeing a vibrant and competitive atmosphere that promotes ongoing advancement and creativity in pediatric healthcare research.
Notable Developments
| Company | Details |
|---|---|
| Thermo Fisher Scientific Inc. | The National Minority Quality Forum (NMQF), an independent non-profit organization dedicated to research and education, and Thermo Fisher Scientific Inc., a leader in the science service industry worldwide, announced in September 2023 that they collaborated to support the expansion of clinical research to historically underserved patient populations through the NMQF's Alliance for Representative Clinical Trials (ARC). |
| Charles River Laboratories International, Inc. | Charles River Laboratories International, Inc. and Chicago, Illinois-based SAMDI Tech, Inc. announced in January 2022 that they were expanding their strategic alliance. As part of the current relationship, which was formed in 2018, SAMDI Tech clients can use Charles River's collection of lead-like compounds for high-throughput screening (HTS). |
| Pfizer | In August 2022, Pfizer presented positive top-line results from its pivotal Phase 3 study on infants in the United States. The study assessed the efficacy of Pfizer's 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for preventing invasive pneumococcal disease (IPD) in pediatric patients by evaluating its 20 Streptococcus pneumoniae serotypes. |
| Sanofi | Among children with eosinophilic esophagitis (EoE) aged 1 to 11, Sanofi's Phase 3 trial produced encouraging results in July 2022. For children with EoE under the age of 12, there are no recognized treatments. |
The pediatric clinical trial market is set to secure a valuation of US$ 17,918.1 million in 2024.
The demand for pediatric clinical trials is estimated to attain US$ 31,661.0 million by 2034.
Sales of pediatric clinical trials are anticipated to evolve at a 5.9% CAGR through 2034.
From 2019 to 2023, the pediatric clinical trial sales registered a 4.4% CAGR.
The oncology segment is set to achieve a market share of 21.8% in 2024.
The industry segment is expected to hold a 50.7% market share in 2024.
The phase 3 segment is set to achieve a market share of 46.9% in 2024.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Area Development/Innovation Trends
4. Value Added Insights
4.1. Total Number of Pediatric Clinical Trials, By Region
4.2. Clinical Trials Share Analysis, By Areas & By Countries
4.3. Clinical Trials Share Analysis of Disease Areas, By Phases & By Countries
4.3.1. Oncology
4.3.2. Infectious Diseases
4.3.3. Cardiovascular Diseases
4.3.4. Metabolic Diseases
4.3.5. Respiratory Diseases
4.3.6. Diabetes
4.3.7. HIV
4.4. Number of Pipeline Products, By Disease Areas
4.5. Oncology Clinical Trial Starts by Year, 2012 to 2022
4.6. Impact of Artificial Intelligence on Industry Clinical Development Pipeline
4.7. Regulatory Scenario, By Country
4.7.1. Regulatory Frameworks in USA
4.7.2. Regulatory Frameworks in Europe
4.7.3. Regulatory Frameworks in Mexico
4.7.4. Regulatory Frameworks in Brazil
4.7.5. Regulatory Frameworks in Australia
4.7.6. Regulatory Frameworks in New Zealand
4.7.7. Regulatory Frameworks in India
4.7.8. Regulatory Frameworks in Malaysia
4.7.9. Regulatory Frameworks in South Korea
4.7.10. Regulatory Frameworks in Japan
4.7.11. Regulatory Frameworks in Taiwan
4.8. Cost Analysis
4.9. PESTEL Analysis
4.10. PORTER Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global Life Expectancy Outlook
5.1.3. R&D Funding By Region
5.1.4. R&D Funding By Country
5.1.5. R&D Spending, By Pharma Players
5.1.6. Top 25 Companies by R&D Spend in 2022
5.1.7. Parent Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Regulatory Initiatives and Incentives
5.2.2. Technological Advancements in Trial Design
5.2.3. Patient-Centric Approaches and Advocacy
5.2.4. Global Collaborations and Partnerships
5.2.5. Increased Focus on Rare Diseases
5.2.6. Inclusive Trial Designs for Diverse Populations
5.2.7. Ethical Considerations and Informed Consent
5.2.8. Advancements in Pediatric Precision Medicine
5.2.9. Integration of Real-World Evidence (RWE)
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022
6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Area
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Million) Analysis by Area, 2018 to 2022
7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Area, 2023 to 2033
7.3.1. Oncology
7.3.2. Infectious Diseases
7.3.3. Cardiovascular Diseases
7.3.4. Metabolic Diseases
7.3.5. Respiratory Diseases
7.3.6. Diabetes
7.3.7. HIV
7.3.8. Other Areas
7.4. Market Attractiveness Analysis By Area
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sponsor Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) By Sponsor Type, 2018 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Sponsor Type, 2023 to 2033
8.3.1. Industry
8.3.2. Government Organizations
8.3.3. Non-Government Organizations
8.3.4. Associations
8.3.5. Others
8.4. Market Attractiveness Analysis By Sponsor Type
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Phases
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) By Phases, 2018 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Phases, 2023 to 2033
9.3.1. Phase 1
9.3.2. Phase 2
9.3.3. Phase 3
9.3.4. Phase 4
9.4. Market Attractiveness Analysis By Phases
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis by Region, 2018 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
10.3.1. North America
10.3.2. Latin America
10.3.3. East Asia
10.3.4. South Asia & Pacific
10.3.5. Western Europe
10.3.6. Eastern Europe
10.3.7. Middle East & Africa
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
11.1. Introduction
11.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
11.3.1. By Country
11.3.1.1. USA
11.3.1.2. Canada
11.3.1.3. Mexico
11.3.2. By Area
11.3.3. By Sponsor Type
11.3.4. By Phases
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Area
11.4.3. By Sponsor Type
11.4.4. By Phases
11.5. Market Trends
11.6. Drivers and Restraints - Impact Analysis
11.7. Country Level Analysis & Forecast
11.7.1. USA Market Analysis
11.7.1.1. Introduction
11.7.1.2. Market Analysis and Forecast by Market Taxonomy
11.7.1.2.1. By Area
11.7.1.2.2. By Sponsor Type
11.7.1.2.3. By Phases
11.7.2. Canada Market Analysis
11.7.2.1. Introduction
11.7.2.2. Market Analysis and Forecast by Market Taxonomy
11.7.2.2.1. By Area
11.7.2.2.2. By Sponsor Type
11.7.2.2.3. By Phases
11.7.3. Mexico Market Analysis
11.7.3.1. Introduction
11.7.3.2. Market Analysis and Forecast by Market Taxonomy
11.7.3.2.1. By Area
11.7.3.2.2. By Sponsor Type
11.7.3.2.3. By Phases
12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Chile
12.3.1.3. Rest of Latin America
12.3.2. By Area
12.3.3. By Sponsor Type
12.3.4. By Phases
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Area
12.4.3. By Sponsor Type
12.4.4. By Phases
12.5. Market Trends
12.6. Drivers and Restraints - Impact Analysis
12.7. Country Level Analysis & Forecast
12.7.1. Brazil Market Analysis
12.7.1.1. Introduction
12.7.1.2. Market Analysis and Forecast by Market Taxonomy
12.7.1.2.1. By Area
12.7.1.2.2. By Sponsor Type
12.7.1.2.3. By Phases
12.7.2. Chile Market Analysis
12.7.2.1. Introduction
12.7.2.2. Market Analysis and Forecast by Market Taxonomy
12.7.2.2.1. By Area
12.7.2.2.2. By Sponsor Type
12.7.2.2.3. By Phases
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. China
13.3.1.2. Japan
13.3.1.3. South Korea
13.3.2. By Area
13.3.3. By Sponsor Type
13.3.4. By Phases
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Area
13.4.3. By Sponsor Type
13.4.4. By Phases
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Country Level Analysis & Forecast
13.7.1. China Market Analysis
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast by Market Taxonomy
13.7.1.2.1. By Area
13.7.1.2.2. By Sponsor Type
13.7.1.2.3. By Phases
13.7.2. Japan Market Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast by Market Taxonomy
13.7.2.2.1. By Area
13.7.2.2.2. By Sponsor Type
13.7.2.2.3. By Phases
13.7.3. South Korea Market Analysis
13.7.3.1. Introduction
13.7.3.2. Market Analysis and Forecast by Market Taxonomy
13.7.3.2.1. By Area
13.7.3.2.2. By Sponsor Type
13.7.3.2.3. By Phases
14. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. India
14.3.1.2. ASEAN Countries
14.3.1.3. Australia & New Zealand
14.3.1.4. Rest of South Asia and Pacific
14.3.2. By Area
14.3.3. By Sponsor Type
14.3.4. By Phases
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Area
14.4.3. By Sponsor Type
14.4.4. By Phases
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Country Level Analysis & Forecast
14.7.1. India Market Analysis
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By Area
14.7.1.2.2. By Sponsor Type
14.7.1.2.3. By Phases
14.7.2. ASEAN Countries Market Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast by Market Taxonomy
14.7.2.2.1. By Area
14.7.2.2.2. By Sponsor Type
14.7.2.2.3. By Phases
14.7.3. Australia & New Zealand Market Analysis
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast by Market Taxonomy
14.7.3.2.1. By Area
14.7.3.2.2. By Sponsor Type
14.7.3.2.3. By Phases
15. Western Europe Market 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. UK
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Nordic Countries
15.3.1.8. Rest of Western Europe
15.3.2. By Area
15.3.3. By Sponsor Type
15.3.4. By Phases
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Area
15.4.3. By Sponsor Type
15.4.4. By Phases
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. Germany Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Area
15.7.1.2.2. By Sponsor Type
15.7.1.2.3. By Phases
15.7.2. France Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Area
15.7.2.2.2. By Sponsor Type
15.7.2.2.3. By Phases
15.7.3. Spain Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Area
15.7.3.2.2. By Sponsor Type
15.7.3.2.3. By Phases
15.7.4. Italy Market Analysis
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast by Market Taxonomy
15.7.4.2.1. By Area
15.7.4.2.2. By Sponsor Type
15.7.4.2.3. By Phases
15.7.5. BENELUX Market Analysis
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast by Market Taxonomy
15.7.5.2.1. By Area
15.7.5.2.2. By Sponsor Type
15.7.5.2.3. By Phases
15.7.6. Nordic Countries Market Analysis
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast by Market Taxonomy
15.7.6.2.1. By Area
15.7.6.2.2. By Sponsor Type
15.7.6.2.3. By Phases
15.7.7. United Kingdom Market Analysis
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast by Market Taxonomy
15.7.7.2.1. By Area
15.7.7.2.2. By Sponsor Type
15.7.7.2.3. By Phases
16. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Russia
16.3.1.2. Hungary
16.3.1.3. Poland
16.3.1.4. Rest of Eastern Europe
16.3.2. By Area
16.3.3. By Sponsor Type
16.3.4. By Phases
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Area
16.4.3. By Sponsor Type
16.4.4. By Phases
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. Russia Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Area
16.7.1.2.2. By Sponsor Type
16.7.1.2.3. By Phases
16.7.2. Hungary Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Area
16.7.2.2.2. By Sponsor Type
16.7.2.2.3. By Phases
16.7.3. Poland Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Area
16.7.3.2.2. By Sponsor Type
16.7.3.2.3. By Phases
17. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Saudi Arabia
17.3.1.2. Türkiye
17.3.1.3. South Africa
17.3.1.4. Other African Union
17.3.1.5. Rest of MEA
17.3.2. By Area
17.3.3. By Sponsor Type
17.3.4. By Phases
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Area
17.4.3. By Sponsor Type
17.4.4. By Phases
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Country Level Analysis & Forecast
17.7.1. Saudi Arabia Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Area
17.7.1.2.2. By Sponsor Type
17.7.1.2.3. By Phases
17.7.2. Türkiye Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Area
17.7.2.2.2. By Sponsor Type
17.7.2.2.3. By Phases
17.7.3. South Africa Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Area
17.7.3.2.2. By Sponsor Type
17.7.3.2.3. By Phases
17.7.4. Other African Union Market Analysis
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast by Market Taxonomy
17.7.4.2.1. By Area
17.7.4.2.2. By Sponsor Type
17.7.4.2.3. By Phases
18. Market Structure Analysis
18.1. Market Share Analysis of Top Sponsors
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Branding & Promotional Strategies by Key Stakeholders
19.4. Key Competitive Deep Dive
19.4.1. Charles River Laboratories, Inc.
19.4.1.1. Overview
19.4.1.2. Services Portfolio
19.4.1.3. Key Financials
19.4.1.4. SWOT Analysis
19.4.1.5. Key Developments
19.4.1.6. Sales Footprint
19.4.1.7. Strategy Overview
19.4.2. Covance, Inc
19.4.3. ICON plc (PRA Health Sciences)
19.4.4. IQVIA
19.4.5. Medpace, Inc.
19.4.6. PAREXEL International
19.4.7. Thermo Fisher Scientific (Pharmaceutical Product Development, LLC)
19.4.8. Syneos Health
19.4.9. Wuxi AppTec
19.4.10. Lonza
19.4.11. Bioclinica, Inc
19.4.12. IBM
19.4.13. McKesson Corporation
19.4.14. Oracle Corporation
19.4.15. Veristat
20. Assumptions and Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Pediatric Clinical Trial Market
